1. Home
  2. |Insights
  3. |Submission of Indirect Cost Rate Proposal Starts Six-Year Limitations Period

Submission of Indirect Cost Rate Proposal Starts Six-Year Limitations Period

Client Alert | 1 min read | 02.01.17

In Sparton DeLeon Springs, LLC (ASBCA Dec. 28, 2016), the Board rejected a government claim for recoupment of alleged overpayments of direct costs as time-barred by the CDA’s six-year statute of limitations. The government alleged that it was not put on notice of the 2007 overpayment until 2014 when Sparton submitted its final voucher, which did not include the direct costs at issue. However, the Board held that the government "knew or should have known" the basis of its claim by 2008 when Sparton submitted its FY 2006 and 2007 indirect cost proposals. Those proposals disclosed direct costs that would be used to calculate indirect rates, but they did not include certain direct costs that the contractor had already invoiced and the government had already paid. Pre-discovery summary judgment was appropriate because "the government should [have] be[en] able to substantiate on its own” whether “interim vouchers contained [sufficient] supporting documentation."

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...